Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Wedbush from $48.00 to $47.00. They now have a "neutral" rating on the stock.
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]